FOLD PE Ratio & Valuation,Is FOLD Overvalued

FOLD Relative Valuation

FOLD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FOLD is overvalued; if below, it's undervalued.

Historical Valuation

Amicus Therapeutics Inc (FOLD) is now in the Fair zone, suggesting that its current forward PS ratio of 4.53 is considered Fairly compared with the five-year average of 3.91. The fair price of Amicus Therapeutics Inc (FOLD) is between 10.14 to 20.95 according to relative valuation methord.

Relative Value

Fair Zone

10.14-20.95

Current Price：10.79

Fair

44.20

28.30

EV/EBITDA

Amicus Therapeutics Inc. (FOLD) has a current EV/EBITDA of 28.30. The 5-year average EV/EBITDA is 40.65. The thresholds are as follows: Strongly Undervalued below -251.21, Undervalued between -251.21 and -105.28, Fairly Valued between 186.57 and -105.28, Overvalued between 186.57 and 332.50, and Strongly Overvalued above 332.50. The current Forward EV/EBITDA of 28.30 falls within the Historic Trend Line -Fairly Valued range.

26.01

EV/EBIT

Amicus Therapeutics Inc. (FOLD) has a current EV/EBIT of 26.01. The 5-year average EV/EBIT is -122.11. The thresholds are as follows: Strongly Undervalued below -1357.91, Undervalued between -1357.91 and -740.01, Fairly Valued between 495.79 and -740.01, Overvalued between 495.79 and 1113.69, and Strongly Overvalued above 1113.69. The current Forward EV/EBIT of 26.01 falls within the Historic Trend Line -Fairly Valued range.

4.53

Amicus Therapeutics Inc. (FOLD) has a current PS of 4.53. The 5-year average PS is 7.04. The thresholds are as follows: Strongly Undervalued below 1.42, Undervalued between 1.42 and 4.23, Fairly Valued between 9.85 and 4.23, Overvalued between 9.85 and 12.66, and Strongly Overvalued above 12.66. The current Forward PS of 4.53 falls within the Historic Trend Line -Fairly Valued range.

6.38

P/OCF

Amicus Therapeutics Inc. (FOLD) has a current P/OCF of 6.38. The 5-year average P/OCF is 1641.98. The thresholds are as follows: Strongly Undervalued below -11766.79, Undervalued between -11766.79 and -5062.41, Fairly Valued between 8346.36 and -5062.41, Overvalued between 8346.36 and 15050.74, and Strongly Overvalued above 15050.74. The current Forward P/OCF of 6.38 falls within the Historic Trend Line -Fairly Valued range.

13.85

P/FCF

Amicus Therapeutics Inc. (FOLD) has a current P/FCF of 13.85. The 5-year average P/FCF is -31.78. The thresholds are as follows: Strongly Undervalued below -276.05, Undervalued between -276.05 and -153.91, Fairly Valued between 90.36 and -153.91, Overvalued between 90.36 and 212.50, and Strongly Overvalued above 212.50. The current Forward P/FCF of 13.85 falls within the Historic Trend Line -Fairly Valued range.

Amicus Therapeutics Inc (FOLD) has a current Price-to-Book (P/B) ratio of 14.12. Compared to its 3-year average P/B ratio of 21.65 , the current P/B ratio is approximately -34.80% higher. Relative to its 5-year average P/B ratio of 18.22, the current P/B ratio is about -22.53% higher. Amicus Therapeutics Inc (FOLD) has a Forward Free Cash Flow (FCF) yield of approximately 0.30%. Compared to its 3-year average FCF yield of -2.42%, the current FCF yield is approximately -112.29% lower. Relative to its 5-year average FCF yield of -4.20% , the current FCF yield is about -107.09% lower.

14.12

P/B

Median3y

21.65

Median5y

18.22

0.30

FCF Yield

Median3y

-2.42

Median5y

-4.20

Competitors Valuation Multiple

The average P/S ratio for FOLD's competitors is 3.84, providing a benchmark for relative valuation. Amicus Therapeutics Inc Corp (FOLD) exhibits a P/S ratio of 4.53, which is 18.01% above the industry average. Given its robust revenue growth of 19.46%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of FOLD increased by 12.00% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -56.53 to -230.72.

The secondary factor is the Revenue Growth, contributed 19.46%to the performance.

Overall, the performance of FOLD in the past 1 year is driven by P/E Change. Which is more unsustainable.

19.46%

141.52M → 169.06M

Revenue Growth

-315.58%

-4.75 → 10.24

Margin Expansion

308.12%

-56.53 → -230.72

P/E Change

12.00%

9.42 → 10.55

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Amicus Therapeutics Inc (FOLD) currently overvalued or undervalued?

What is Amicus Therapeutics Inc (FOLD) fair value?

FOLD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Amicus Therapeutics Inc (FOLD) is between 10.14 to 20.95 according to relative valuation methord.

How does FOLD's valuation metrics compare to the industry average?

What is the current P/B ratio for Amicus Therapeutics Inc (FOLD) as of Dec 16 2025?

As of Dec 16 2025, Amicus Therapeutics Inc (FOLD) has a P/B ratio of 14.12. This indicates that the market values FOLD at 14.12 times its book value.

What is the current FCF Yield for Amicus Therapeutics Inc (FOLD) as of Dec 16 2025?

As of Dec 16 2025, Amicus Therapeutics Inc (FOLD) has a FCF Yield of 0.30%. This means that for every dollar of Amicus Therapeutics Inc’s market capitalization, the company generates 0.30 cents in free cash flow.

What is the current Forward P/E ratio for Amicus Therapeutics Inc (FOLD) as of Dec 16 2025?

As of Dec 16 2025, Amicus Therapeutics Inc (FOLD) has a Forward P/E ratio of 44.20. This means the market is willing to pay $44.20 for every dollar of Amicus Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Amicus Therapeutics Inc (FOLD) as of Dec 16 2025?

As of Dec 16 2025, Amicus Therapeutics Inc (FOLD) has a Forward P/S ratio of 4.53. This means the market is valuing FOLD at $4.53 for every dollar of expected revenue over the next 12 months.

FOLD Valuation